TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect

Deep News

Yesterday

TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a trading value of HK$54.34 million.

The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that TRANSTHERA-B has been added to the Stock Connect eligible list, effective from September 8th. Additionally, TRANSTHERA-B recently announced that the company's core product Tinengotinib (TT-00420) in combination with CStone Pharmaceuticals (Cayman) Limited's Cosibelimab (PD-1/CTLA-4) and Cejemly (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) has completed the first patient dosing in an open-label, multicenter Phase II clinical study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1160465691"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160465691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160465691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160465691","market":"nz","top_or_hot":-1,"title":"TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect","media":"Deep News","content":"<p>TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a trading value of HK$54.34 million.</p>\n<p>The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that TRANSTHERA-B has been added to the Stock Connect eligible list, effective from September 8th. Additionally, TRANSTHERA-B recently announced that the company's core product Tinengotinib (TT-00420) in combination with CStone Pharmaceuticals (Cayman) Limited's Cosibelimab (PD-1/CTLA-4) and Cejemly (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) has completed the first patient dosing in an open-label, multicenter Phase II clinical study.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-08 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a trading value of HK$54.34 million.</p>\n<p>The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that TRANSTHERA-B has been added to the Stock Connect eligible list, effective from September 8th. Additionally, TRANSTHERA-B recently announced that the company's core product Tinengotinib (TT-00420) in combination with CStone Pharmaceuticals (Cayman) Limited's Cosibelimab (PD-1/CTLA-4) and Cejemly (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) has completed the first patient dosing in an open-label, multicenter Phase II clinical study.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSTECH","symbol_name":"恒生科技指数","start_time":0,"source_url":"","article_id":"1160465691","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160465691","pubTimestamp":1757298056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSTECH":"恒生科技指数","07226":"南方两倍做多恒科","YANG":"三倍做空富时中国ETF-Direxion","02617":"药捷安康-B","HSCEI":"国企指数","BK4614":"Manus概念股","BK1161":"生物科技"},"translate_title":"TRANSTHERA-B早盘大涨近11%创上市新高公司加入沪股通","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"07226":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a trading value of HK$54.34 million.\nThe Shanghai Stock Exchange and Shenzhen Stock Exchange announced that TRANSTHERA-B has been added to the Stock Connect eligible list, effective from September 8th. Additionally, TRANSTHERA-B recently announced that the company's core product Tinengotinib (TT-00420) in combination with CStone Pharmaceuticals (Cayman) Limited's Cosibelimab (PD-1/CTLA-4) and Cejemly (Ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC) has completed the first patient dosing in an open-label, multicenter Phase II clinical study.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}